BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsClinical readout

- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule - Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88% - Clinical validation further demonstrates Arrowhead’s position as the leading innovator in siRNA therapies - PASADENA, Calif.

Related news

ARWRArrowhead Pharmaceuticals2026-07-27 11:30 EST

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

ARWRArrowhead Pharmaceuticals2026-08-24 11:30 EST

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

BIIBBiogen2026-09-03 23:30 EST

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

BIIBBiogen2026-09-01 11:30 EST

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

PHVSPharvaris2026-09-08 10:50 EST

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

RAREUltragenyx Pharmaceutical2026-09-01 20:05 EST

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

PHVSPharvaris2026-08-06 10:50 EST

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-26 13:05 EST

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-09-15 11:30 EST

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

ARWRArrowhead Pharmaceuticals2026-08-30 15:30 EST

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

ARWRArrowhead Pharmaceuticals2026-08-24 11:30 EST

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

ARWRArrowhead Pharmaceuticals2026-08-17 13:33 EST

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Stock data

Close
67.74 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States